Related Experiment Video
Updated: Jul 15, 2026
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Intraocular use of rituximab
A S Kitzmann1, J S Pulido, B G Mohney
1Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.
Eye (London, England)
|April 28, 2007
Summary
Intravitreal rituximab at 1 mg showed no ocular toxicity in rabbit models and human patients with intraocular lymphoma. This suggests rituximab is a potentially safe treatment for ocular conditions.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Intraocular lymphoma is a rare malignancy requiring effective treatment.
- Rituximab, a monoclonal antibody, has shown efficacy in systemic lymphomas.
Observation:
- A study evaluated the safety of 1 mg intravitreal rituximab in rabbits and human patients.
- Rabbit eyes and human eyes with intraocular lymphoma were treated and monitored.
Findings:
- No light microscopic evidence of ocular toxicity was observed in rabbit eyes one month post-injection.
- Human eyes treated with intravitreal rituximab showed no intraocular toxicity during a median follow-up of 3.6 months.
Implications:
- Intravitreal rituximab at 1 mg appears to be a safe therapeutic option for intraocular lymphoma.
- Further research may explore the efficacy of intravitreal rituximab in other ocular diseases.
